SDAI’s Strategic Leap: Joint Venture with LiveBeyond Targets China’s Booming Anti-Aging Market

Key Takeaways for Investors: Major Biotechnology Transformation and China Expansion

SDAI Limited (SGX: SDAI), a Singapore-based company listed on the Catalist Board, has announced a potentially game-changing partnership that could have significant implications for its future growth and share price. SDAI will collaborate with LiveBeyond Pte. Ltd., a leading longevity and anti-aging research company, to jointly pursue research, development, and commercialisation in the anti-aging industry. This move marks a clear commitment by SDAI to transform itself into a biotechnology leader, with an explicit focus on tapping into China’s fast-growing anti-aging market.

Highlights of the Strategic Cooperation Agreement

• Joint Venture in Hainan, China: SDAI and LiveBeyond have agreed to establish a joint venture in Hainan, a business-friendly free trade zone in China, to develop anti-aging products and healthcare services. The details of the joint venture, including financial arrangements and shareholdings, will be announced once finalised.
• Focus on Cutting-Edge Biotechnologies: Areas of collaboration include stem cells, genetic engineering, exosomes, and bio-based materials. The companies aim to target sectors such as medical treatments, healthcare, and skincare with new, innovative products.
• Access to World-Class Expertise: The LiveBeyond research team is led by Professor Brian Kennedy, a globally renowned authority on the biology of aging. Professor Kennedy is a Distinguished Professor at the National University of Singapore and leads the Healthy Longevity Translational Research Programme. He is supported by a team of more than ten internationally recognised longevity professors, enhancing SDAI’s access to deep scientific expertise.
• China Market Opportunity: China’s anti-aging market is projected to almost double from US\$544.8 million in 2024 to US\$1.076 billion by 2035. This growth is driven by an aging population, favorable government policies, and increasing consumer spending on longevity products—a potentially lucrative opportunity for the SDAI-LiveBeyond partnership.

What Shareholders Need to Know—Potentially Price-Sensitive Information

• Strategic Transformation Underway: SDAI is clearly signaling its intention to transform from its traditional businesses into a biotechnology-focused company, with a specialisation in healthcare and anti-aging. This strategic shift could significantly re-rate the company if executed successfully, especially given the market size and high-growth potential of the sector.
• Exposure to Fast-Growing Chinese Market: The joint venture in Hainan provides SDAI with a direct entry point into the Chinese market, which is experiencing robust growth and offers scale that few other markets can match.
• Collaboration with Leading Scientists: The partnership with LiveBeyond gives SDAI access to cutting-edge research and a global network of longevity experts, potentially accelerating product development and commercialisation.
• Further Announcements Expected: Investors should note that the agreement is at a strategic cooperation stage. Final details of the joint venture (structure, financial terms, product pipeline) are pending and will be announced later. These could be material events for the share price.
• Due Diligence Warning: SDAI has stated that information about LiveBeyond and its team was provided by LiveBeyond and has not been independently verified by SDAI or its board. Investors should await further disclosures and due diligence.

Management Commentary and Vision

Madam Hao Dongting, Executive Chairperson of SDAI, emphasised that this collaboration is a key step in accelerating SDAI’s transformation into a biotechnology company. By working with Professor Brian Kennedy and his team, SDAI aims to identify gaps in the current anti-aging market and drive innovation to meet evolving consumer demands. She views the partnership as an opportunity for knowledge exchange and technical advancement, underscoring the group’s commitment to long-term value creation for shareholders.

About SDAI Limited

SDAI has been listed on the Singapore Exchange Catalist Board since 2011. It is undergoing a strategic shift towards biotechnology, focusing on integrating biotech in the medical, skincare, and health products industries, with the ambition of becoming a leading force in the field.

Investor Action Points

• Monitor upcoming announcements regarding the final structure and details of the joint venture with LiveBeyond.
• Watch for updates on the product development pipeline and any early commercialisation milestones.
• Consider the risks associated with early-stage biotech transformations, as well as the upside potential in a high-growth sector.

For further information, visit www.sdai.com.sg or contact Woodnote Consulting at the details provided in the announcement.

Disclaimer: This article is for informational and educational purposes only and does not constitute financial advice or a recommendation to buy or sell any securities. Readers should conduct their own due diligence or consult a licensed financial advisor before making investment decisions. The author and publisher are not responsible for any losses resulting from investment decisions made based on this article. The information on LiveBeyond has not been independently verified by SDAI or the board as per the company’s announcement.

View SDAI Historical chart here